VistaGen Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on June 12, 2015. The Company is a Nevada corporation focused on the development of orally-available new prodrug candidates, specifically AV-101 for Major Depressive Disorder and other central nervous system disorders.
Key Financial Metrics and Capital Structure Changes
The filing details significant debt-to-equity conversions rather than standard operating financial metrics.
- Debt Conversion (June 12, 2015): Approximately $5.3 million of outstanding debt was converted into 750,918 shares of Series B 10% Convertible Preferred Stock.
- Cumulative Debt Conversion (Mid-May to June 12, 2015): Including prior conversions reported on May 13 and May 22, 2015, a total of approximately $14.4 million of indebtedness has been converted and cancelled.
- Legal Fee Restructuring: A letter agreement with Morrison & Foerster LLP (MF) resulted in the conversion of Note B (approx. $1.4 million principal plus accrued interest) into 257,143 shares of Series B Preferred. Collection on Note A (approx. $917,000) was withheld.
- Warrant Amendment: MF warrants to purchase 110,448 shares of common stock were amended to extend the expiration date to September 15, 2019, and set the exercise price at $20.00 per share.
Material Changes Versus Prior Period
The primary material change is the reduction of the Company's debt load through the conversion of approximately $14.4 million in obligations into equity since mid-May 2015. This action alters the capital structure by increasing the number of outstanding preferred shares and reducing immediate cash debt obligations.
Guidance, Outlook, and Securities Terms
Series B Preferred Terms:
- Dividend: 10% per annum, accruing and payable only in unregistered common stock upon conversion.
- Voluntary Conversion: Convertible at the holder's option into common stock at a fixed price of $7.00 per share.
- Automatic Conversion Triggers:
- A strategic transaction involving AV-101 with at least $10.0 million in upfront cash.
- A registered public offering with at least $10.0 million in gross proceeds.
- Common stock trading at least 20,000 shares per day for 20 consecutive days with a closing price of at least $12.00 per share.
Outlook and Disclosure: The Company plans to meet with analysts and investors on or after June 16, 2015, to provide information regarding AV-101. The filing text does not provide specific revenue, profit, or cash flow figures for the period.
Investor Verification Checklist
- Verify the total outstanding debt remaining after the $14.4 million conversion.
- Confirm the dilution impact of the 1,008,061 total Series B Preferred shares issued (750,918 + 257,143) upon conversion to common stock at the $7.00 fixed price.
- Review the full text of the Certificate of Designation for Series B Preferred (Exhibit 3.1) for additional rights and preferences.
- Monitor the upcoming investor presentation (Exhibit 99.1) for updates on AV-101 clinical development and potential strategic transaction timelines.
- Assess the liquidity implications of the withheld collection on the $917,000 Note A owed to Morrison & Foerster LLP.